NEW YORK (GenomeWeb News) — Mirus Bio has received a two-year, $900,000 Phase II Small Business Innovative Research grant to develop its microRNA-labeling technology for clinical research and “potential diagnostic applications,” the company said today.
The Madison, Wis.-based miRNA and siRNA transfection company said it will use the money to develop products that will study the link between miRNAs and undisclosed diseases that it will eventually “enable diagnostic testing for miRNAs as biomarkers for disease.”

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Consulting company McKinsey says diagnostics companies will have to combine genomic data analysis, electronic medical records, effective reimbursement strategies, and regulatory compliance in order to win.

A new report has found that researchers in Africa are still heavily dependent on funding from organizations in the US, Europe, and China, Nature News says.

An article in The Atlantic argues that the progress being made in science isn't keeping pace with the money and time being spent on research.

In Science this week: a CRISPR screen identifies sideroflexin 1 as a requisite component of one-carbon metabolism, and more.

Sponsored by
Advanced Cell Diagnostics

This webinar will demonstrate how a research team at the National Institutes of Health evaluated a novel in situ hybridization approach and applied it to study splice variants related to schizophrenia.

Sponsored by
Sophia Genetics

This webinar will discuss the use of clinical-grade exome analysis application in complex case investigations.